American Society of Hirudotherapy

A novel thrombin inhibitory peptide discovered from leech using affinity chromatography combined with ultra-high performance liquid chromatography-high resolution mass spectroscopy

Research article published in J Chromatogr B Analyt Technol Biomed Life Sci (2020)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportSalivary PharmacologyDrug DevelopmentHuang Q et al. · J Chromatogr B Analyt Technol Biomed Life Sci, 2020

Abstract

Thrombin (THR) inhibitors play an important role in the treatment of thrombotic diseases. This study established a THR-based bio-specific extraction coupled with affinity chromatography and ultra-high performance liquid chromatography-high resolution mass spectroscopy (UPLC-HR-MS) analysis method to screen and identify THR ligands in Leech. After evaluating the reliability of the screening method using positive control drug (hirudin), it was successfully used to screen the potential active constituents in leech. And a comprehensive analysis of the peptides in leech elution was performed by UPLC-HR-MS, a total of 34 peptides were identified. At the same time, anti-THR activity was explored and inferred by searching databases and published literature. As a result, six peptides were discovered to be potential active compounds in leech. Further, the six peptides were synthesized and in vitro enzymatic activity assay was performed. Finally, SYELPDGQVITIGNER was screened as an anti-THR peptide with an IC50 value of 255.75 µM and it was discovered for the first time from Whitmania pigra Whitman and Hirudo nipponica Whitman. The molecular docking study showed that THR inhibitory activity of the polypeptide was mainly attributed to the hydrogen bond interactions, van der Waals forces and electrostatic interactions interaction between polypeptide and THR. These results suggest that the polypeptide is a potential natural THR inhibitor that can be used as anticoagulant.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Summary

Using thrombin affinity extraction validated with hirudin, the authors screened leech material and identified 34 peptides; the synthesized peptide SYELPDGQVITIGNER inhibited thrombin with an IC50 of 255.75 µM, first found in Whitmania pigra and Hirudo nipponica.

Why This Matters for Hirudotherapy

This study established a thrombin-based bio-specific extraction method using affinity chromatography and UPLC-HR-MS to screen and identify thrombin ligands in leech material, validating the approach with hirudin as a positive control. From 34 identified peptides, six were selected for synthesis and in vitro enzymatic assay, yielding a 16-amino-acid peptide (SYELPDGQVITIGNER) with thrombin inhibitory activity (IC50 of 255.75 µM), discovered for the first time from Whitmania pigra and Hirudo nipponica. This work identifies a novel potential anticoagulant peptide from leeches. These findings are based on in vitro enzymatic assay and molecular docking only; no in vivo, clinical, or whole-organism hirudotherapy data are presented.

Citation

Reference (Vancouver style)

Huang Q, Gao Q, Chai X, Ren W, Zhang G, Kong Y, et al. A novel thrombin inhibitory peptide discovered from leech using affinity chromatography combined with ultra-high performance liquid chromatography-high resolution mass spectroscopy. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1151:122153. doi:10.1016/j.jchromb.2020.122153. PMID: 32512533

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.